Orchestra BioMed presents data showing sustained blood pressure drops
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Why BofA says July Fed rate hike would be "unprecedented"
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
September 4, 2025 5:00 PM EDTResults from long-term follow up of patients treated with atrioventricular interval modulation (AVIM) therapy show blood pressure-lowering effects are sustained for years after activation, reversible with no observed rebound hypertension upon deactivation of treatment, and reproducible upon reactivation following a washout periodSimultaneous peer-reviewed publication of AVIM therapy mechanistic and clinical results Orchestra BioMed and Medtronic (NYSE: MDT) have a strategic collaboration to develop and commercialize AVIM therapy for the treatment of uncontrolled hypertension in patients indicated for a... More
